Covaxin WHO Approval News: Bharat Biotech Chairman and MD said THIS about WHO Emergency Use Listing - check all details here

On Monday, Bharat Biotech said that the company has submitted all documents required for Emergency Use Listing (EUL) of Covaxin to World Health Organisation (WHO) on July 9, 2021.

Bharat Biotech said the company now expects that they would receive the EUL for the indigenous COVID-19 vaccine Covaxin at the earliest. Source: PTI

Covaxin WHO Approval News: Bharat Biotech said on Monday (July 12) that the company has submitted all documents required for Emergency Use Listing (EUL) of Covaxin to World Health Organisation (WHO) on July 9, 2021. Bharat Biotech said the company now expects that they would receive the EUL for the indigenous COVID-19 vaccine Covaxin at the earliest.

See Zee Business Live TV Streaming Below:

TRENDING NOW

Bharat Biotech also tweeted the statement of Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech International Limited from its official Twitter handle. Dr. Ella said, "All documents required for Emergency Use Listing (EUL) of COVAXIN have been submitted to WHO as of 9th July. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest."

COVAXIN® EUL pic.twitter.com/dCilH7KbSk

— BharatBiotech (@BharatBiotech) July 12, 2021

It has to be noted that the nationwide COVID-19 vaccination drive started with Covishield and Covaxin from January 16, 2021. As per an ANI report, a WHO pre-qualification or EUL is necessary for a vaccine company to supply vaccine for global facilities such as Covax or international procurement.

The ANI report states that the WHO has approved the COVID-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/SII, Johnson and Johnson Janssen, Moderna and Sinopharm for emergency use.

As per the ANI report, Covaxin showed 63.6 per cent efficacy against the Delta variant of COVID-19 which has also spread in other countries as well. The indigenous vaccine Covaxin shows 93.4 per cent efficacy against symptomatic COVID and 63.6 per cent efficacy against asymptomatic COVID-19.

The trial was conducted on 25,800 subjects and the data submitted to the Subject Expert Committee (SEC) showed that the vaccine was 'well-tolerated'.

TAGS: